1. Home
  2. BLX vs ADPT Comparison

BLX vs ADPT Comparison

Compare BLX & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banco Latinoamericano de Comercio Exterior S.A.

BLX

Banco Latinoamericano de Comercio Exterior S.A.

HOLD

Current Price

$53.77

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$12.70

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLX
ADPT
Founded
1977
2009
Country
Panama
United States
Employees
372
N/A
Industry
Commercial Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.3B
IPO Year
1997
2019

Fundamental Metrics

Financial Performance
Metric
BLX
ADPT
Price
$53.77
$12.70
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$17.78
AVG Volume (30 Days)
119.3K
1.5M
Earning Date
04-27-2026
05-05-2026
Dividend Yield
5.13%
N/A
EPS Growth
N/A
63.89
EPS
N/A
N/A
Revenue
N/A
$276,976,000.00
Revenue This Year
$18.36
$3.98
Revenue Next Year
$9.95
$22.72
P/E Ratio
$8.26
N/A
Revenue Growth
N/A
54.77
52 Week Low
$38.41
$8.50
52 Week High
$57.79
$20.76

Technical Indicators

Market Signals
Indicator
BLX
ADPT
Relative Strength Index (RSI) 50.54 39.36
Support Level $52.31 $12.22
Resistance Level $55.30 $13.45
Average True Range (ATR) 1.34 0.77
MACD -0.25 -0.14
Stochastic Oscillator 51.65 10.52

Price Performance

Historical Comparison
BLX
ADPT

About BLX Banco Latinoamericano de Comercio Exterior S.A.

Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: